Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT01232296
- Locations
- 🇹🇭
Novartis Investigative Site, Songkla, Thailand
Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)
- Conditions
- Interventions
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2010-10-29
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 60
- Registration Number
- NCT01230697
- Locations
- 🇮🇹
Alfredo Berruti, Orbassano (To), Turin, Italy
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 564
- Registration Number
- NCT01223027
- Locations
- 🇺🇸
Deke Slayton Cancer Center Deke Slayton Cancer Center (2), Webster, Texas, United States
🇺🇸University of Kansas Cancer Center Univ of KS, Kansas City, Kansas, United States
🇺🇸Rockwood Clinic Spokane Location, Spokane, Washington, United States
Sorafenib in Urothelium Cancer of Bladder
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Association of Urologic Oncology (AUO)
- Target Recruit Count
- 98
- Registration Number
- NCT01215266
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2011-06-15
- Lead Sponsor
- Ministry of Health, Labour and Welfare, Japan
- Target Recruit Count
- 190
- Registration Number
- NCT01214343
- Locations
- 🇯🇵
Hiroshima City Hospital, Hiroshima, Japan
🇯🇵Hiroshima University Hospital, Hiroshima, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
- Conditions
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 277
- Registration Number
- NCT01197170
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Emory University
- Target Recruit Count
- 25
- Registration Number
- NCT01194869
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT01189370
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 278
- Registration Number
- NCT01187199
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
- Conditions
- Interventions
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 180
- Registration Number
- NCT01183663
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.